Ocular Therapeutix adds Riad Sherif to board, Hong to resign

Ocular Therapeutix, Inc. disclosed in a Form 8-K dated November 6, 2026 that its Board of Directors, acting on the recommendation of its Nominating and Corporate Governance Committee, added Riad Sherif, M.D., to the board effective that day.¹ He was named a Class I director, a term running through the company's 2027 annual stockholders meeting or until a successor is elected.¹

Sherif's background spans ophthalmology and pharma leadership. He has been CEO and a board member of Oculis Holding AG, described as a clinical-stage biopharmaceutical company, since December 2017.¹ Earlier he was an Entrepreneur in Residence at the Novartis Venture Fund from June 2016 to September 2017, and before that served as Region President for Europe, Middle East and Africa at Alcon, Novartis AG's eye care division, from March 2014 to May 2016.¹ From 2002 to 2014 he held several Novartis roles, including global sales leadership for Transplant and Immunology and regional posts in Latin America, and he co-founded the vaccine manufacturing joint venture Sinergium Biotech.¹ He began his career at Sanofi from 1993 to 2000.¹ He has also sat on the board of Revenio Group Oyj since March 2022.¹

The filing states there were no arrangements tied to his election and no related-party transactions requiring disclosure.¹ Under the company's standard non-employee director pay policy, he was granted an option for 88,000 shares at $6.60, matching Ocular Therapeutix's Nasdaq closing price that day, plus 28,000 restricted stock units, both vesting over three years.¹

Separately, Seung Suh Hong, Ph.D. notified the company of his resignation from the board on November 6, 2026, effective December 31, 2026.¹ The company said the departure does not stem from any disagreement over operations, policies or practices.¹